Clinical TrialsRoche’s Sefaxersen Cuts Proteinuria in Phase III IgA Nephropathy Study Roche’s Sefaxersen Cuts Proteinuria in Phase III IgA Nephropathy Study Read Post »
Clinical TrialsORKA-001 Sustains Deep Psoriasis Clearance Through Week 28 After Two Doses ORKA-001 Sustains Deep Psoriasis Clearance Through Week 28 After Two Doses Read Post »
Clinical TrialsImmunovant Ends IMVT-1402 Development in Cutaneous Lupus After CLE Study Mi... Immunovant Ends IMVT-1402 Development in Cutaneous Lupus After CLE Study Mi... Read Post »
Clinical TrialsVarespladib Misses Phase 2 BRAVIO Primary Endpoints but Shows Signals in Kr... Varespladib Misses Phase 2 BRAVIO Primary Endpoints but Shows Signals in Kr... Read Post »
Clinical TrialsTegoprubart Shows Promising 24-Month Kidney Function Advantage Over Tacroli... Tegoprubart Shows Promising 24-Month Kidney Function Advantage Over Tacroli... Read Post »
Clinical TrialsViking’s VK2735 Maintains Most Weight Loss with Less Frequent Dosing Viking’s VK2735 Maintains Most Weight Loss with Less Frequent Dosing Read Post »
Clinical TrialsAmgen’s Dazodalibep Meets Phase 3 Endpoint in Sjögren’s Disease Amgen’s Dazodalibep Meets Phase 3 Endpoint in Sjögren’s Disease Read Post »
Clinical TrialsOtsuka Reports Positive Phase 3 FUSION Results in FUS-ALS Otsuka Reports Positive Phase 3 FUSION Results in FUS-ALS Read Post »
Clinical TrialsInaxaplin Reduces Proteinuria in Phase 2b AMPLIFIED AMKD Trial Inaxaplin Reduces Proteinuria in Phase 2b AMPLIFIED AMKD Trial Read Post »
Clinical TrialsFasedienol Shows Progressive Improvement in Social Anxiety During PALISADE-... Fasedienol Shows Progressive Improvement in Social Anxiety During PALISADE-... Read Post »
Clinical TrialsElunetirom Shows Positive Phase 2 Results in Bipolar Depression Elunetirom Shows Positive Phase 2 Results in Bipolar Depression Read Post »
Clinical TrialsRoche’s Enicepatide Shows Positive Results in Phase II T2D Trial Roche’s Enicepatide Shows Positive Results in Phase II T2D Trial Read Post »
Clinical TrialsBlinatumomab Replacing Chemotherapy Improves 4-Year Event-Free Survival in ... Blinatumomab Replacing Chemotherapy Improves 4-Year Event-Free Survival in ... Read Post »
Clinical TrialsRilzabrutinib Sustains Platelet Responses in LUNA3 ITP Study Rilzabrutinib Sustains Platelet Responses in LUNA3 ITP Study Read Post »
Clinical TrialsALKS 7290 Shows Dose-Dependent ADHD Symptom Improvements ALKS 7290 Shows Dose-Dependent ADHD Symptom Improvements Read Post »
Clinical TrialsCagriSema Shows Greater Weight Loss With Non-Inferior HbA1c Reduction CagriSema Shows Greater Weight Loss With Non-Inferior HbA1c Reduction Read Post »
Clinical TrialsCAPLYTA Shows Encouraging Results in Bipolar I Mania in New Study CAPLYTA Shows Encouraging Results in Bipolar I Mania in New Study Read Post »
Clinical TrialsTeva’s UZEDY Shows Real-World Benefits in Schizophrenia Teva’s UZEDY Shows Real-World Benefits in Schizophrenia Read Post »
Clinical TrialsAbbisko’s Lavengratinib Shows Early Growth Benefit in Children with A... Abbisko’s Lavengratinib Shows Early Growth Benefit in Children with A... Read Post »
Clinical TrialsTEV-‘749 Shows Durable Results in Phase 3 Schizophrenia Trial TEV-‘749 Shows Durable Results in Phase 3 Schizophrenia Trial Read Post »
Clinical TrialsHansoh’s HS-10374 Delivers Promising Phase 3 Results in Plaque Psoriasis Hansoh’s HS-10374 Delivers Promising Phase 3 Results in Plaque Psoriasis Read Post »
Clinical TrialsLong-Acting Antibodies Delay HIV Rebound After ART Interruption, RIO Trial ... Long-Acting Antibodies Delay HIV Rebound After ART Interruption, RIO Trial ... Read Post »
Clinical TrialsCSL Seqirus aQIVc Shows Stronger Immune Response in Phase 3 CSL Seqirus aQIVc Shows Stronger Immune Response in Phase 3 Read Post »
Clinical TrialsSanofi’s SAR443820 Fails Phase 2 HIMALAYA Trial in ALS, Ending RIPK1 Prog... Sanofi’s SAR443820 Fails Phase 2 HIMALAYA Trial in ALS, Ending RIPK1 Prog... Read Post »
Clinical TrialsBiogen Reports Positive Adolescent Data for Empaveli in C3G and IC-MPGN Biogen Reports Positive Adolescent Data for Empaveli in C3G and IC-MPGN Read Post »
Clinical TrialsSotyktu Shows Durable Efficacy in Psoriatic Arthritis at 2 Years Sotyktu Shows Durable Efficacy in Psoriatic Arthritis at 2 Years Read Post »
Clinical TrialsRoche’s Lunsumio Combination Improves Progression-Free Survival in Phase ... Roche’s Lunsumio Combination Improves Progression-Free Survival in Phase ... Read Post »
Clinical TrialsNovo’s Denecimig Shows Tolerability After Direct Switch from Emicizumab i... Novo’s Denecimig Shows Tolerability After Direct Switch from Emicizumab i... Read Post »
Clinical TrialsNovartis Discontinues Lifonebart Development in ALS After ASTRALS Phase 2 F... Novartis Discontinues Lifonebart Development in ALS After ASTRALS Phase 2 F... Read Post »
Clinical TrialsLongeveron Laromestrocel Misses ELPIS II HLHS Endpoint Longeveron Laromestrocel Misses ELPIS II HLHS Endpoint Read Post »
Clinical TrialsRozanolixizumab Shows Limited Benefit in Severe Fibromyalgia Phase 2A Trial Rozanolixizumab Shows Limited Benefit in Severe Fibromyalgia Phase 2A Trial Read Post »
Clinical TrialsBoehringer Ingelheim Stops EASi-KIDNEY Trial of Vicadrostat in Chronic Kidn... Boehringer Ingelheim Stops EASi-KIDNEY Trial of Vicadrostat in Chronic Kidn... Read Post »
Clinical TrialsCan a Decades-Old Heart Drug Break Up Cancer Cell Clusters? Can a Decades-Old Heart Drug Break Up Cancer Cell Clusters? Read Post »
Clinical TrialsSKY-0515 Shows 1.59-Point cUHDRS Benefit in Huntington’s Disease SKY-0515 Shows 1.59-Point cUHDRS Benefit in Huntington’s Disease Read Post »
Clinical TrialsSYNT-101 Shows Placebo-Adjusted Weight Loss in 28-Day Phase 1 Obesity Study SYNT-101 Shows Placebo-Adjusted Weight Loss in 28-Day Phase 1 Obesity Study Read Post »
Clinical TrialsLilly Advances Obesity and Diabetes Pipeline With New EASD 2026 Data Lilly Advances Obesity and Diabetes Pipeline With New EASD 2026 Data Read Post »
Clinical TrialsNX210c Phase 2 ALS Trial Shows Reduced Functional Decline NX210c Phase 2 ALS Trial Shows Reduced Functional Decline Read Post »
Clinical TrialsRademikibart Improves Lung Function at Day 7 in Phase 2 Asthma Trial; Treat... Rademikibart Improves Lung Function at Day 7 in Phase 2 Asthma Trial; Treat... Read Post »
Clinical TrialsXKH004 Delivers Phase 3 Efficacy in Ankylosing Spondylitis With 45.4% ASAS4... XKH004 Delivers Phase 3 Efficacy in Ankylosing Spondylitis With 45.4% ASAS4... Read Post »
Clinical TrialsIvonescimab Shows Sustained Overall Survival Benefit in EGFR-Mutated NSCLC ... Ivonescimab Shows Sustained Overall Survival Benefit in EGFR-Mutated NSCLC ... Read Post »
Clinical TrialsTRUTAKNA Stabilized Kidney Function and Reduced Risk of Kidney Disease Prog... TRUTAKNA Stabilized Kidney Function and Reduced Risk of Kidney Disease Prog... Read Post »
Clinical TrialsContineum’s JNJ-5120/PIPE-307 Misses Phase 2 MDD Endpoint Contineum’s JNJ-5120/PIPE-307 Misses Phase 2 MDD Endpoint Read Post »
Clinical TrialsRevelyx Bio’s Recombinant Botulinum Toxin YY003 Shows 80.8% Response in P... Revelyx Bio’s Recombinant Botulinum Toxin YY003 Shows 80.8% Response in P... Read Post »
Clinical TrialsTrastuzumab Botidotin Improves Progression-Free Survival Versus T-DM1 in HE... Trastuzumab Botidotin Improves Progression-Free Survival Versus T-DM1 in HE... Read Post »
Clinical TrialsCorbus’s CRB-913 Shows 5% Weight Loss in Phase 1b Obesity Trial Corbus’s CRB-913 Shows 5% Weight Loss in Phase 1b Obesity Trial Read Post »
Clinical TrialsEnhertu Extends Progression-Free Survival by Six Months in First-Line HER2-... Enhertu Extends Progression-Free Survival by Six Months in First-Line HER2-... Read Post »
Clinical TrialsZipalertinib Plus Chemotherapy Improves Progression-Free Survival in First-... Zipalertinib Plus Chemotherapy Improves Progression-Free Survival in First-... Read Post »
Clinical TrialsZidesamtinib Shows 94% Response Rate in ROS1-Positive NSCLC Zidesamtinib Shows 94% Response Rate in ROS1-Positive NSCLC Read Post »
Clinical TrialsRis-Rez Extends Survival in Relapsed Small Cell Lung Cancer in Phase III AR... Ris-Rez Extends Survival in Relapsed Small Cell Lung Cancer in Phase III AR... Read Post »
Clinical TrialsRoche’s Tam-Peli Cuts Death Risk by 54% in SCLC Trial Roche’s Tam-Peli Cuts Death Risk by 54% in SCLC Trial Read Post »
